Hematopoietic stem cell transplantation (HSCT) remains the only curative option for several
hematological malignancies. Its use has continued to grow, with an estimated 23,500 …

Background: In recipients of allogeneic hematopoietic stem cell transplantation (HSCT),
organ toxicity is a barrier to administering high-intensity conditioning regimens. We …

Hematopoietic stem cell transplant is an established treatment modality for a variety of
neoplastic, hematologic, and immunologic disorders. Fueled in part by remarkable …

Allogeneic hematopoietic stem cell transplantation is a potent curative treatment for
hematological malignancies, but relapse is still a major problem. Donor lymphocyte infusion …

Overview The role of the various conditioning (or “preparative”) regimens is dependent upon
the desired effect regarding both diagnosis and stem cell source. Antineoplastic effects are …

Allogeneic stem cell transplantation (allo-SCT) for haematological malignancies became a
safer approach in recent years, for example, owing to improved supportive strategies …

Allogeneic stem cell transplantation (allo-SCT) after a reduced-intensity conditioning (RIC)
protocol is associated with decreased short-term toxicity. This suggests that the procedure …

Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the treatment
of choice for many patients suffering from hematological malignancies, severe …

OBJECTIVES: To review recent research of long-term complications and prevention
techniques in hematopoietic stem cell transplantation (HSCT). DATA SOURCES: Peer …

BACKGROUND: Adverse events (AEs) after hematopoietic progenitor cell (HPC) infusion
are rare but might be life‐threatening. These reactions have traditionally been associated …